265 related articles for article (PubMed ID: 32520594)
21. Increased proportion of time in hybrid closed-loop "Auto Mode" is associated with improved glycaemic control for adolescent and young patients with adult type 1 diabetes using the MiniMed 670G insulin pump.
Duffus SH; Ta'ani ZA; Slaughter JC; Niswender KD; Gregory JM
Diabetes Obes Metab; 2020 Apr; 22(4):688-693. PubMed ID: 31709736
[TBL] [Abstract][Full Text] [Related]
22. Glycemic Effects and Predictors of Increased Time-in-Range After Initiating MiniMed 670G: A 12-Month Observational Study.
Jacobsen SS; Hommel E; Ranjan AG; Nørgaard K
Diabetes Technol Ther; 2022 Aug; 24(8):592-597. PubMed ID: 35099298
[TBL] [Abstract][Full Text] [Related]
23. In-Clinic Evaluation of the MiniMed 670G System "Suspend Before Low" Feature in Children with Type 1 Diabetes.
Wood MA; Shulman DI; Forlenza GP; Bode BW; Pinhas-Hamiel O; Buckingham BA; Kaiserman KB; Liljenquist DR; Bailey TS; Shin J; Huang S; Chen X; Cordero TL; Lee SW; Kaufman FR
Diabetes Technol Ther; 2018 Nov; 20(11):731-737. PubMed ID: 30299976
[TBL] [Abstract][Full Text] [Related]
24. Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes.
Carlson AL; Sherr JL; Shulman DI; Garg SK; Pop-Busui R; Bode BW; Lilenquist DR; Brazg RL; Kaiserman KB; Kipnes MS; Thrasher JR; Reed JHC; Slover RH; Philis-Tsimikas A; Christiansen M; Grosman B; Roy A; Vella M; Jonkers RAM; Chen X; Shin J; Cordero TL; Lee SW; Rhinehart AS; Vigersky RA
Diabetes Technol Ther; 2022 Mar; 24(3):178-189. PubMed ID: 34694909
[No Abstract] [Full Text] [Related]
25. Efficacy and Safety of Real-Life Usage of MiniMed 670G Automode in Children with Type 1 Diabetes Less than 7 Years Old.
Salehi P; Roberts AJ; Kim GJ
Diabetes Technol Ther; 2019 Aug; 21(8):448-451. PubMed ID: 31166801
[TBL] [Abstract][Full Text] [Related]
26. Hybrid Closed-Loop with Faster Insulin Aspart Compared with Standard Insulin Aspart in Very Young Children with Type 1 Diabetes: A Double-Blind, Multicenter, Randomized, Crossover Study.
Ware J; Allen JM; Boughton CK; Cezar A; Hartnell S; Wilinska ME; Thankamony A; Deakin M; Leyland H; Phelan K; Thornborough K; Hovorka R
Diabetes Technol Ther; 2023 Jun; 25(6):431-436. PubMed ID: 36880866
[TBL] [Abstract][Full Text] [Related]
27. Glycemic Outcomes During Real-World Hybrid Closed-Loop System Use by Individuals With Type 1 Diabetes in the United States.
Arunachalum S; Velado K; Vigersky RA; Cordero TL
J Diabetes Sci Technol; 2023 Jul; 17(4):951-958. PubMed ID: 35414272
[TBL] [Abstract][Full Text] [Related]
28. Glucose Control in Adults with Type 1 Diabetes Using a Medtronic Prototype Enhanced-Hybrid Closed-Loop System: A Feasibility Study.
Lee MH; Vogrin S; Paldus B; Jones HM; Obeyesekere V; Sims C; Wyatt SA; Ward GM; McAuley SA; MacIsaac RJ; Krishnamurthy B; Sundararajan V; Jenkins AJ; O'Neal DN
Diabetes Technol Ther; 2019 Sep; 21(9):499-506. PubMed ID: 31264889
[No Abstract] [Full Text] [Related]
29. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.
Haidar A; Legault L; Dallaire M; Alkhateeb A; Coriati A; Messier V; Cheng P; Millette M; Boulet B; Rabasa-Lhoret R
CMAJ; 2013 Mar; 185(4):297-305. PubMed ID: 23359039
[TBL] [Abstract][Full Text] [Related]
30. Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes.
Collyns OJ; Meier RA; Betts ZL; Chan DSH; Frampton C; Frewen CM; Hewapathirana NM; Jones SD; Roy A; Grosman B; Kurtz N; Shin J; Vigersky RA; Wheeler BJ; de Bock MI
Diabetes Care; 2021 Apr; 44(4):969-975. PubMed ID: 33579715
[TBL] [Abstract][Full Text] [Related]
31. Switching from Suspend-Before-Low Insulin Pump Technology to a Hybrid Closed-Loop System Improves Glucose Control and Reduces Glucose Variability: A Retrospective Observational Case-Control Study.
Lepore G; Scaranna C; Corsi A; Dodesini AR; Trevisan R
Diabetes Technol Ther; 2020 Apr; 22(4):321-325. PubMed ID: 31617752
[TBL] [Abstract][Full Text] [Related]
32. Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial.
Thrasher J; Polsky S; Hovsepian L; Nowotny I; Pierre S; Bois De Fer B; Bhargava A; Mukherjee B; Garg SK
Diabetes Technol Ther; 2020 Sep; 22(9):666-673. PubMed ID: 31833801
[No Abstract] [Full Text] [Related]
33. Faster Compared With Standard Insulin Aspart During Day-and-Night Fully Closed-Loop Insulin Therapy in Type 1 Diabetes: A Double-Blind Randomized Crossover Trial.
Dovc K; Piona C; Yeşiltepe Mutlu G; Bratina N; Jenko Bizjan B; Lepej D; Nimri R; Atlas E; Muller I; Kordonouri O; Biester T; Danne T; Phillip M; Battelino T
Diabetes Care; 2020 Jan; 43(1):29-36. PubMed ID: 31575640
[TBL] [Abstract][Full Text] [Related]
34. Simple meal announcements and pramlintide delivery versus carbohydrate counting in type 1 diabetes with automated fast-acting insulin aspart delivery: a randomised crossover trial in Montreal, Canada.
Cohen E; Tsoukas MA; Legault L; Vallis M; Von Oettingen JE; Palisaitis E; Odabassian M; Yale JF; Garfield N; Gouchie-Provencher N; Rutkowski J; Jafar A; Ghanbari M; Haidar A
Lancet Digit Health; 2024 Jul; 6(7):e489-e499. PubMed ID: 38906614
[TBL] [Abstract][Full Text] [Related]
35. Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial.
Garg SK; Grunberger G; Weinstock R; Lawson ML; Hirsch IB; DiMeglio LA; Pop-Busui R; Philis-Tsimikas A; Kipnes M; Liljenquist DR; Brazg RL; Kudva YC; Buckingham BA; McGill JB; Carlson AL; Criego AB; Christiansen MP; Kaiserman KB; Griffin KJ; Forlenza GP; Bode BW; Slover RH; Keiter A; Ling C; Marinos B; Cordero TL; Shin J; Lee SW; Rhinehart AS; Vigersky RA;
Diabetes Technol Ther; 2023 Jan; 25(1):1-12. PubMed ID: 36472543
[No Abstract] [Full Text] [Related]
36. Prospective Analysis of the Impact of Commercialized Hybrid Closed-Loop System on Glycemic Control, Glycemic Variability, and Patient-Related Outcomes in Children and Adults: A Focus on Superiority Over Predictive Low-Glucose Suspend Technology.
Beato-Víbora PI; Gallego-Gamero F; Lázaro-Martín L; Romero-Pérez MDM; Arroyo-Díez FJ
Diabetes Technol Ther; 2020 Dec; 22(12):912-919. PubMed ID: 31855446
[No Abstract] [Full Text] [Related]
37. Maximizing Glycemic Benefits of Using Faster Insulin Formulations in Type 1 Diabetes: In Silico Analysis Under Open- and Closed-Loop Conditions.
Diaz C JL; Colmegna P; Breton MD
Diabetes Technol Ther; 2023 Apr; 25(4):219-230. PubMed ID: 36595379
[No Abstract] [Full Text] [Related]
38. An analysis of Medtronic MiniMed 670G insulin pump use in clinical practice and the impact on glycemic control, quality of life, and compliance.
Horowitz ME; Kaye WA; Pepper GM; Reynolds KE; Patel SR; Knudson KC; Kale GK; Gutierrez ME; Cotto LA; Horowitz BS
Diabetes Res Clin Pract; 2021 Jul; 177():108876. PubMed ID: 34058303
[TBL] [Abstract][Full Text] [Related]
39. Performance of Fast-Acting Aspart Insulin as Compared to Aspart Insulin in Insulin Pump for Managing Type 1 Diabetes Mellitus: A Meta-Analysis.
Dutta D; Mohindra R; Mahajan K; Sharma M
Diabetes Metab J; 2023 Jan; 47(1):72-81. PubMed ID: 35746893
[TBL] [Abstract][Full Text] [Related]
40. Six-Month Effectiveness of Advanced
Tornese G; Buzzurro F; Carletti C; Faleschini E; Barbi E
Front Endocrinol (Lausanne); 2021; 12():766314. PubMed ID: 34858339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
